Some uses of this neonicotinoid are proposed for phase out to protect bees and other pollinators
OTTAWA, May 31, 2018 /CNW/ - Canadians care about how the use of pesticides impacts the environment. The Government of Canada relies on scientific evidence to evaluate pesticides so that they are used safely and do not threaten
Health Canada's scientific assessment of imidacloprid looked at the effects of this pesticide on pollinators such as honey bees, bumble bees and solitary bees. The assessment found that there are some uses of imidacloprid that may pose a risk to bees. The Department is therefore proposing significant restrictions on the use of imidacloprid products to protect bees and other pollinators. These proposed restrictions include the cancellation of some uses, restrictions on the timing of use, and new product labels.
Consultations on this proposed decision will be open to the public for 90 days. Comments received during this consultation will be considered along with input from previous consultations, including separate restrictions that were proposed in 2016 to protect aquatic insects. We expect to publish a final decision on the overall use of imidacloprid in Canada in December 2018.
Health Canada's primary objective in regulating pesticides is to protect the health of Canadians and the environment. All pesticides must undergo a rigorous science-based review before being approved for sale in Canada.
Related ProductsBackgrounder: Proposed Re-evaluation Decision: Imidacloprid — Pollinator (Bee) Assessment
Associated LinksPRVD2018-12: Proposed Re-evaluation Decision on Imidacloprid (Pollinator Assessment) PRVD2016-20: Proposed Re-evaluation Decision on Imidacloprid December 2017 Update on Neonicotinoid Pesticides PRVD2017-23: Proposed Re-evaluation Decision on Clothianidin and Its Associated End-use Products: Pollinator Re-evaluation PRVD2017-24: Proposed Re-evaluation Decision on Thiamethoxam and Its Associated End-use Products: Pollinator Re-evaluation Update on Bee Incident Reports 2012-2016
SOURCE Health Canada
Subscribe to our Free Newsletters!
Mastocytosis is a rare condition marked by accumulation of mast cells under the skin and various ...
Lusutrombopag is used to treat abnormally low platelet counts (thrombocytopenia) in adult patients ...
Stereotypic movement disorder (SMD) is a motor disorder, associated with neurodevelopmental ...View All